Our research paper of the month presents the results of the ‘SWIFT direct’ trial, a randomised, open-label, blinded-outcome trial, aiming to investigate whether thrombectomy alone would be non-inferior to thrombectomy plus intravenous alteplase in patients with acute ischaemic stroke due to anterior circulation large vessel occlusion.
In this population-based study, the authors aimed to investigate whether increased life expectancy determined by the adherence to a healthy lifestyle has an impact on the overall years lived with AD across the lifespan.
To evaluate the association of COVID-19 infection with olfactory bulb, our authors of the month conducted this multicenter postmortem cohort study, using ultrastructural and histopathological analysis.
Our authors of the month conducted this retrospective case-control study in order to investigate the association of AD with the risk of COVID-19 infection (adjusted for comorbidities and sociodemographic factors).
Our paper of the month describes a study led by Stanford University researchers, which now provides a mechanistic basis for how EBV infection can trigger the patient’s immune cells to attack self-tissue within the CNS.
Our authors of the month conducted a longitudinal, multi-modal brain imaging study using the UK biobank, whereby participants had already been scanned before getting infected with SARS-CoV-2, offering a unique resource to elucidate these questions.
Our authors of the month conducted a systematic retrospective analysis of 150 lumbar punctures in 127 patients with PCR-proven COVID-19 and neurological symptoms seen at 17 European university centres.
Our authors of the month conducted a systematic review and meta-analysis in order to summarise the frequency of neurologic manifestations in patients with COVID-19 and to investigate the association of these manifestations with disease severity and mortality.
For February we have selected Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomized, placebo-controlled trial.